- Home
- BLBD vs JANX Comparison
BLBD vs JANX Comparison
Compare BLBD & JANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BLBD
- JANX
- Stock Information
- Founded
- BLBD 1927
- JANX 2017
- Country
- BLBD United States
- JANX United States
- Employees
- BLBD N/A
- JANX N/A
- Industry
- BLBD Construction/Ag Equipment/Trucks
- JANX Biotechnology: Pharmaceutical Preparations
- Sector
- BLBD Consumer Discretionary
- JANX Health Care
- Exchange
- BLBD Nasdaq
- JANX Nasdaq
- Market Cap
- BLBD 1.3B
- JANX 1.4B
- IPO Year
- BLBD N/A
- JANX 2021
- Fundamental
- Price
- BLBD $44.95
- JANX $25.15
- Analyst Decision
- BLBD Strong Buy
- JANX Strong Buy
- Analyst Count
- BLBD 7
- JANX 8
- Target Price
- BLBD $56.79
- JANX $90.63
- AVG Volume (30 Days)
- BLBD 392.9K
- JANX 711.6K
- Earning Date
- BLBD 08-06-2025
- JANX 08-06-2025
- Dividend Yield
- BLBD N/A
- JANX N/A
- EPS Growth
- BLBD 31.05
- JANX N/A
- EPS
- BLBD 3.22
- JANX N/A
- Revenue
- BLBD $1,356,302,000.00
- JANX $9,336,000.00
- Revenue This Year
- BLBD $9.64
- JANX N/A
- Revenue Next Year
- BLBD $7.99
- JANX $1,470.82
- P/E Ratio
- BLBD $14.13
- JANX N/A
- Revenue Growth
- BLBD 7.57
- JANX 28.12
- 52 Week Low
- BLBD $30.04
- JANX $22.48
- 52 Week High
- BLBD $55.60
- JANX $71.71
- Technical
- Relative Strength Index (RSI)
- BLBD 67.01
- JANX 54.41
- Support Level
- BLBD $44.02
- JANX $23.52
- Resistance Level
- BLBD $45.93
- JANX $24.87
- Average True Range (ATR)
- BLBD 1.27
- JANX 1.13
- MACD
- BLBD 0.04
- JANX 0.33
- Stochastic Oscillator
- BLBD 70.41
- JANX 70.90
About BLBD Blue Bird Corporation
Blue Bird Corp is an American bus manufacturing company. It is an independent designer and manufacturer of school buses. The company operates in two segments; the Bus segment which involves the design, engineering, manufacture, and sales of school buses and extended warranties; and the Parts segment which includes the sales of replacement bus parts. Geographically, the company generates a majority of its revenue from its customers in the United States and the rest from Canada and Rest of the world.
About JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.